scholarly journals Cell cycle-regulated degradation of Xenopus cyclin B2 requires binding to p34cdc2.

1994 ◽  
Vol 5 (7) ◽  
pp. 713-724 ◽  
Author(s):  
H M van der Velden ◽  
M J Lohka

The protein kinase activity of the cell cycle regulator p34cdc2 is inactivated when the mitotic cyclin to which it is bound is degraded. The amino (N)-terminus of mitotic cyclins includes a conserved "destruction box" sequence that is essential for degradation. Although the N-terminus of sea urchin cyclin B confer cell cycle-regulated degradation to a fusion protein, a truncated protein containing only the N-terminus of Xenopus cyclin B2, including the destruction box, is stable under conditions where full length molecules are degraded. In an attempt to identify regions of cyclin B2, other than the destruction box, involved in degradation, the stability of proteins encoded by C-terminal deletion mutants of cyclin B2 was examined in Xenopus egg extracts. Truncated cyclin with only the first 90 amino acids was stable, but other C-terminal deletions lacking between 14 and 187 amino acids were unstable and were degraded by a mechanism that was neither cell cycle regulated nor dependent upon the destruction box. None of the C-terminal deletion mutants bound p34cdc2. To investigate whether the binding of p34cdc2 is required for cell cycle-regulated degradation, the behavior of proteins encoded by a series of full length Xenopus cyclin B2 cDNA with point mutations in conserved amino acids in the p34cdc2-binding domain was examined. All of the point mutants failed to form stable complexes with p34cdc, and their degradation was markedly reduced compared to wild-type cyclin. Similar results were obtained when the mutant cyclins were synthesized in reticulocyte lysates and when cyclin mRNA was translated directly in a Xenopus egg extract. These results indicate that mutations that interfere with p34cdc2 binding also interfere with cyclin destruction, suggesting that p34cdc2 binding is required for the cell cycle-regulated destruction of Xenopus cyclin B2.

1998 ◽  
Vol 79 (05) ◽  
pp. 985-991 ◽  
Author(s):  
William P. Fay ◽  
Lakshmi V. Bokka

SummaryStreptokinase (SK) is a 414 amino acid bacterial protein that activates human plasminogen. Streptokinase fragments derived from the central portion of the protein bind plasminogen, but are inactive, indicating that the amino- and/or carboxyl-termini are required for normal plasminogen activator activity. To better define the function of the N- and C-termini of SK we generated and characterized 21 N-terminal and 20 C-terminal deletion mutants. All mutants lacking ≥18 N-terminal or ≥51 C-terminal amino acids exhibited markedly reduced plasminogen activator activity, while mutants lacking ≤12 N-terminal or ≤40 C-terminal residues were fully active. The decrease in SK activity with N-terminal deletion appeared to result not from loss of plasminogen binding capacity, but rather from increased susceptibility of deletion mutants to degradation by plasmin. Point mutations at positions 13 (SK V13D) or 20 (SK V20D) produced functional abnormalities similar to those observed in N-terminal deletion mutants, with SK V13D exhibiting delayed amidolytic activity and SK V20D exhibiting only 1% plasminogen activator activity and marked sensitivity to degradation by plasmin. C-terminal deletion mutants lacking ≥51 amino acids also bound plasminogen, but did not induce significant amidolytic activity in plasminogen or activator activity in plasmin. Prevention of cleavage at position 59 of SK had no effect on plasminogen activator activity, suggesting that the rapid hydrolysis of this bond that occurs after SK-plasminogen complex formation is not required for normal function of the N-terminus. These results suggest that residues within or near positions 13-20 of SK are important determinants of its capacity to generate amidolytic activity and are a critical determinant of the stability of SK, while residues within or near position 364-374 are required for generating amidolytic activity and for conferring plasminogen activator activity to plasmin(ogen). These results also suggest that SK fragments significantly smaller than SK 13-374 are unlikely to be effective thrombolytic agents.


2001 ◽  
Vol 75 (14) ◽  
pp. 6329-6336 ◽  
Author(s):  
T. Arazi ◽  
Y. M. Shiboleth ◽  
A. Gal-On

ABSTRACT Systematic deletion and peptide tagging of the amino-terminal domain (NT, ∼43 amino acids) of an attenuated zucchini yellow mosaic potyvirus (ZYMV-AGII) coat protein (CP) were used to elucidate its role in viral systemic infection. Deletion mutants truncated by 8, 13, and 33 amino acid residues from the CP-NT 5′ end were systemically infectious and produced symptoms similar to those of the AGII virus. Tagging these deletion mutants with either human c-Myc (Myc) or hexahistidine peptides maintained viral infectivity. Similarly, addition of these peptides to the intact AGII CP-NT did not affect viral life cycle. To determine which parts, if any, of the CP-NT are essential for viral systemic infection, a series of Myc-tagged mutants with 8 to 43 amino acids removed from the CP-NT were constructed. All Myc-tagged CP-NT deletion mutants, including those from which virtually all the viral CP-NT had been eliminated, were able to encapsidate and cause systemic infection. Furthermore, chimeric viruses with deletions of up to 33 amino acids from CP-NT produced symptoms indistinguishable from those caused by the parental AGII virus. In contrast to CP-NT Myc fusion, addition of the foot-and-mouth disease virus (FMDV) immunogenic epitope to AGII CP-NT did not permit systemic infection. However, fusion of the Myc peptide to the N terminus of the FMDV peptide restored the capability of the virus to spread systemically. We have demonstrated that all CP-NT fused peptides were exposed on the virion surface, masking natural CP immunogenic determinants. Our findings demonstrate that CP-NT is not essential for ZYMV spread and that it can be replaced by an appropriate foreign peptide while maintaining systemic infectivity.


2018 ◽  
Vol 49 (5) ◽  
pp. 1987-1998 ◽  
Author(s):  
Mashael R. Al-Anazi ◽  
Nyla Nazir ◽  
Dilek Colak ◽  
Mohammed N. Al-Ahdal ◽  
Ahmed A. Al-Qahtani

Background/Aims: The hepatitis B virus X protein (HBx) is a viral trans-activator that plays a crucial role in pathogenesis of hepatocellular carcinoma (HCC) via an unknown mechanism. The role of HBx in modulating cell proliferation and programmed cell death is replete with controversies. Thus, the goal of this study was to elucidate the effect of HBx and its deletion mutants on cell cycle progression in human hepatoma cells. Methods: Huh7 cells transfected with either full-length or truncated HBx were tested for their mitogenic potential based on their effect on the expression of key cell cycle-related proteins (p27, cyclin D1, p21, and p53) and pro-apoptotic proteins such as cleaved poly (ADP-ribose) polymerase (PARP) and Bax. Western blotting and immunofluorescence techniques were applied to detect changes in the expression levels and intracellular localization, respectively, of the investigated proteins. Also, Quantitative real-time PCR (qRT-PCR) was used to detect changes in RNA levels. Results: An increased anchorage-independent growth of cells transfected with HBx-WT and its deletion mutants was observed. The cell cycle regulatory molecules were differentially modulated by full-length HBx (1-154) and its different N- and C-terminal truncated forms (HBx (31-154), HBx (61-154), HBx (1-94), and HBx (61-124)). An enhanced modulation of p27, p21, and cyclin D1 was associated with HBx (1-154), whereas p53 expression was significantly inhibited by HBx (61-124). Similarly, the expression of cleaved PARP and Bax was efficiently suppressed by HBx (1-94) and HBx (61-154). Conclusion: The HBx-WT and its mutants play a critical role in the pathogenesis and progression of HCC by modulating cell cycle regulatory proteins.


2001 ◽  
Vol 69 (12) ◽  
pp. 7839-7850 ◽  
Author(s):  
Gillian D. Pullinger ◽  
R. Sowdhamini ◽  
Alistair J. Lax

ABSTRACT The locations of the catalytic and receptor-binding domains of thePasteurella multocida toxin (PMT) were investigated. N- and C-terminal fragments of PMT were cloned and expressed as fusion proteins with affinity tags. Purified fusion proteins were assessed in suitable assays for catalytic activity and cell-binding ability. A C-terminal fragment (amino acids 681 to 1285) was catalytically active. When microinjected into quiescent Swiss 3T3 cells, it induced changes in cell morphology typical of toxin-treated cells and stimulated DNA synthesis. An N-terminal fragment with a His tag at the C terminus (amino acids 1 to 506) competed with full-length toxin for binding to surface receptors and therefore contains the cell-binding domain. The inactive mutant containing a mutation near the C terminus (C1165S) also bound to cells in this assay. Polyclonal antibodies raised to the N-terminal PMT region bound efficiently to full-length native toxin, suggesting that the N terminus is surface located. Antibodies to the C terminus of PMT were microinjected into cells and inhibited the activity of toxin added subsequently to the medium, confirming that the C terminus contains the active site. Analysis of the PMT sequence predicted a putative transmembrane domain with predicted hydrophobic and amphipathic helices near the N terminus over the region of homology to the cytotoxic necrotizing factors. The C-terminal end of PMT was predicted to be a mixed α/β domain, a structure commonly found in catalytic domains. Homology to proteins of known structure and threading calculations supported these assignments.


2007 ◽  
Vol 88 (8) ◽  
pp. 2320-2328 ◽  
Author(s):  
Christian Klewitz ◽  
Hans-Dieter Klenk ◽  
Jan ter Meulen

Lassa virus glycoprotein 2 (LASV GP-2) belongs to the class I fusion protein family. Its N terminus contains two stretches of highly conserved hydrophobic amino acids (residues 260–266 and 276–298) that have been proposed as N-terminal or internal fusion peptide segments (N-FPS, I-FPS) by analogy with similar sequences of other viral glycoproteins or based on experimental data obtained with synthetic peptides, respectively. By using a pH-dependent, recombinant LASV glycoprotein mediated cell–cell fusion assay and a retroviral pseudotype infectivity assay, an alanine scan of all hydrophobic amino acids within both proposed FPSs was performed. Fusogenicity and infectivity were correlated, both requiring correct processing of the glycoprotein precursor. Most point mutations in either FPS accounted for reduced or abolished fusion or infection, respectively. Some mutations also had an effect on pre-fusion steps of virus entry, possibly by inducing structural changes in the glycoprotein. The data demonstrate that several amino acids from both hydrophobic regions of the N terminus, some of which (W264, G277, Y278 and L280) are 100 % conserved in all arenaviruses, are involved in fusogenicity and infectivity of LASV GP-2.


2010 ◽  
Vol 299 (1) ◽  
pp. F243-F254 ◽  
Author(s):  
Mikiko Ito ◽  
Aya Sakurai ◽  
Keiji Hayashi ◽  
Akiko Ohi ◽  
Natsumi Kangawa ◽  
...  

The type IIc Na+-dependent phosphate cotransporter (NaPi-IIc) is specifically targeted to, and expressed on, the apical membrane of renal proximal tubular cells and mediates phosphate transport. In the present study, we investigated the signals that determine apical expression of NaPi-IIc with a focus on the role of the N- and the C-terminal tails of mouse NaPi-IIc in renal epithelial cells [opossum kidney (OK) and Madin-Darby canine kidney cells]. Wild-type NaPi-IIc, the cotransporter NaPi-IIa, as well as several IIa-IIc chimeras and deletion mutants, were fused to enhanced green fluorescent protein (EGFP), and their cellular localization was analyzed in polarized renal epithelial cells by confocal microscopy and by cell-surface biotinylation. Fluorescent EGFP-fused NaPi-IIc transporter proteins are correctly expressed in the apical membrane of OK cells. The apical expression of N-terminal deletion mutants (deletion of N-terminal 25, 50, or 69 amino acids) was not affected by truncation. In contrast, C-terminal deletion mutants (deletion of C-terminal 45, 50, or 62 amino acids) did not have correct apical expression. A more detailed mutational analysis indicated that a domain (amino acids WLHSL) in the cytoplasmic C terminus is required for apical expression of NaPi-IIc in renal epithelial cells. We conclude that targeting of NaPi-IIc to the apical cell surface is regulated by a unique amino acid motif in the cytoplasmic C-terminal domain.


1992 ◽  
Vol 3 (11) ◽  
pp. 1279-1294 ◽  
Author(s):  
H Kobayashi ◽  
E Stewart ◽  
R Poon ◽  
J P Adamczewski ◽  
J Gannon ◽  
...  

The binding of cyclin A to p34cdc2 and p32cdk2 and the protein kinase activity of the complexes has been measured by cell-free translation of the corresponding mRNA in extracts of frog eggs, followed by immunoprecipitation. A variety of mutant cyclin A molecules have been constructed and tested in this assay. Small deletions and point mutations of highly conserved residues in the 100-residue "cyclin box" abolish binding and activation of both p34cdc2 and p32cdk2. By contrast, large deletions at the N-terminus have no effect on kinase binding and activation, until they remove residues beyond 161, where the first conserved amino acids are found in all known examples of cyclin A. At the C-terminus, removal of 14 or more amino acids abolishes activity. We also demonstrate that deletion of, or point mutations, in the cyclin A homologue of the 10-residue "destruction box," previously described in cyclin B (Glotzer et al., 1991) abolish cyclin proteolysis at the transition from M-phase to interphase.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3116-3116
Author(s):  
Nimisha Sharma ◽  
Elena Solomaha ◽  
Federico Simone ◽  
Michael Thirman

Abstract The ELL gene was first cloned as a fusion partner of MLL in the (11;19)(q23;p13.1) translocation that occurs in acute myeloid leukemia. Subsequently, the ELL2 gene was cloned on the basis of its sequence homology to ELL. Both proteins stimulate the rate of transcript elongation by RNA polymerase II. Previously, we isolated two closely related proteins, EAF1 and EAF2, which interact with ELL and ELL2. Deletion mapping studies carried out to delineate the domain(s) of ELL involved in its interaction with either EAF1 or EAF2 showed that the N-terminus (amino acids 1–207) of ELL binds to both EAF1 and EAF2. In comparison, the middle region (207–411 amino acids) does not bind to either of the two EAF proteins and the C-terminus region (411–621 amino acids) binds only to the EAF1 protein. Biochemical studies have revealed that EAF1 and EAF2 enhance the rate of mRNA chain elongation by the ELL proteins in vitro. Although both ELL and ELL2 have similar roles in transcriptional elongation, ELL2 has not been shown to be involved in any hematological abnormality so far. In an attempt to gain a deeper understanding of the biology and functions of the interactions between these different proteins, we determined the kinetic properties of these interactions using the biophysical techniques of surface plasmon resonance (SPR) and isothermal calorimetry (ITC). SPR detects complex formation in real time and provides a better comprehension of the dynamics of association and dissociation of an interaction, and ITC is used to determine the thermodynamics of the interaction. Our SPR analysis has provided novel insights into the nature of the binding of the ELL proteins to the EAF proteins. We observed that both ELL and ELL2 bind to EAF1 and EAF2 with a high affinity, but the binding affinity of ELL2 for both EAF1 and EAF2 is almost twelve-fold greater than the affinity of ELL for both the EAF proteins. The higher affinity of ELL2 is due to much slower uptake and release kinetics reflected by the low association and dissociation rate constants of ELL2 compared to ELL. The stoichiometry of ELL, ELL2, EAF1 and EAF2 in the ELL-EAF1, ELL-EAF2, ELL2-EAF1 and ELL2-EAF2 complexes was estimated to be 1:1 after fitting the respective sensorgrams obtained by SPR analysis to the Langmuir’s bimolecular model. Interestingly, we did not observe any difference in the affinity of either ELL or ELL2 for binding to EAF1 or EAF2. We used SPR-based competition experiments to show that ELL and ELL2 bind to the same sites on the EAF proteins. We have also investigated the characteristics of binding of the various ELL domains to the EAF1/2 proteins. In the (11;19)(q23;p13.1) translocation, the C-terminus of ELL fuses to the N-terminus of MLL to generate a chimeric protein that interacts with EAF1 and this interaction is critical for the role of ELL in cell immortalization in vitro and leukemogenesis in vivo. In agreement with this observation, we found that the C-terminus of ELL binds EAF1 with a higher affinity than EAF2, while the N-terminus of ELL binds with similar affinities and displays similar kinetics of binding to both EAF1 and EAF2. We also found that the individual binding sites on the ELL N-terminus and the C-terminus exhibited a lower affinity for the EAF proteins, but the affinity increases when the two sites function together in the context of the full-length protein, suggesting that the two sites co-operate with each other to increase the affinity for the full-length ELL protein. Taken together, these observations suggest that although ELL and ELL2 share many similarities in terms of their sequence and function in transcription elongation, they bind to the EAF proteins with different affinities and kinetics. Alternative interaction dynamics and the interplay between the different ELL and EAF proteins permit distinct functional regulation of transcriptional elongation in normal and leukemic cells.


Sign in / Sign up

Export Citation Format

Share Document